Sugi Predict

Sugi Predict / Compounds / SCHEMBL3870079

SCHEMBL3870079

SCHEMBL3870079

Cc1ccc(-c2ccc(C(=O)NCCc3ccc(C(C)N4CCCCC4)cc3)cc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.57
▸ MCHR1 Q99705 9/20 0.55
▸ CHRM1 P11229 2/20 0.54
▸ HTR2A P28223 2/20 0.54
▸ CYP2D6 P10635 1/20 0.54
▸ NPC1 O15118 2/20 0.52
▸ RAB9A P51151 2/20 0.52
▸ TP53 P04637 3/20 0.52
▸ LMNA P02545 3/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.49
▸ KDM4E B2RXH2 1/20 0.47
▸ USP2 O75604 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ MEN1 O00255 1/20 0.46
▸ KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3870885 1.00 ALDH1A1 (0.57) ALDH1A1MCHR1CHRM1HTR2ACYP2D6
SCHEMBL3872340 0.99 ALDH1A1 (0.58) ALDH1A1MCHR1CHRM1HTR2ACYP2D6
SCHEMBL3873969 0.91 MCHR1 (0.55) ALDH1A1MCHR1CHRM1HTR2ACYP2D6
SCHEMBL3870571 0.91 MCHR1 (0.55) ALDH1A1MCHR1CHRM1HTR2ACYP2D6
SCHEMBL3870762 0.90 MCHR1 (0.66) ALDH1A1MCHR1CHRM1HTR2ACYP2D6
SCHEMBL3869900 0.90 NPC1 (0.51) ALDH1A1MCHR1CHRM1HTR2ACYP2D6
SCHEMBL3875273 0.90 MCHR1 (0.69) MCHR1CHRM1HTR2ACYP2D6NPC1
SCHEMBL3878626 0.90 MCHR1 (0.66) ALDH1A1MCHR1CHRM1HTR2ACYP2D6
SCHEMBL3869879 0.90 MCHR1 (0.69) MCHR1CHRM1HTR2ACYP2D6NPC1
SCHEMBL3868712 0.90 MCHR1 (0.55) ALDH1A1MCHR1CHRM1HTR2ACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7601868-B2 Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-13 — — US disclosed
US-7601868-B2 Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-13 — — US disclosed
US-7601868-B2 Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-13 — — US disclosed
US-20060128690-A1 Amine derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-15 — — US disclosed
EP-1593667-A1 AMINE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2005-11-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128690-A1 Amine derivative MC1R, MC2R, MC4R ALDH1A1 332/4885MCHR1 4/4885CHRM1 217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.